drugset / Trial / NCT04913649

Intravenous Iron to Treat Postoperative Anemia in Older Cardiac Surgery Patients

NCT04913649

Phase 4 Recruiting 310 enrolled dr. P. Noordzij Pharmacosmos A/S · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

Postoperative anemia is common in cardiac surgery with cardiopulmonary bypass. Iron deficiency delays the recovery from postoperative anemia and may negatively affect the postoperative trajectory of cardiac surgery patients. The objective of the study is to determine the effect of treatment of postoperative iron deficiency anemia with intravenous iron on disability 90 days after surgery. This will be evaluated in a randomized placebo-controlled double blind two-center trial in which 310 elective cardiac surgery patients will be included.

Timeline

Start
2021-09-23
Primary completion
2026-11
Completion
2026-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Ferric Derisomaltose Unknown 20 mg/kg Intravenous